<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="http://hdl.handle.net/10174/29502">
    <title>DSpace Collection:</title>
    <link>http://hdl.handle.net/10174/29502</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="http://hdl.handle.net/10174/41340" />
        <rdf:li rdf:resource="http://hdl.handle.net/10174/41161" />
        <rdf:li rdf:resource="http://hdl.handle.net/10174/41160" />
        <rdf:li rdf:resource="http://hdl.handle.net/10174/41158" />
      </rdf:Seq>
    </items>
    <dc:date>2026-04-06T19:41:00Z</dc:date>
  </channel>
  <item rdf:about="http://hdl.handle.net/10174/41340">
    <title>AI-driven tools for non-invasive skin analysis: A study in detecting lentigines and nevi in human skin</title>
    <link>http://hdl.handle.net/10174/41340</link>
    <description>Title: AI-driven tools for non-invasive skin analysis: A study in detecting lentigines and nevi in human skin
Authors: Silva, Pedro; Silva, Liliana; Vieira, Pedro; Pinto, Pedro
Abstract: This study demonstrates that deep learning models, particularly YOLOv4 and Faster R-CNN, can effectively detect and segment facial hyperpigmentation with high accuracy. The integration of classical image processing and a user-friendly GUI makes the system accessible to clinicians and researchers. These results highlight the potential of AI to enhance dermatological diagnostics and support longitudinal skin health monitoring.</description>
    <dc:date>2025-03-31T23:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/10174/41161">
    <title>Pharmacogenomic Biomarkers as a Source of evidence for Effectiveness and Safety in Alzheimer’s Disease Therapy</title>
    <link>http://hdl.handle.net/10174/41161</link>
    <description>Title: Pharmacogenomic Biomarkers as a Source of evidence for Effectiveness and Safety in Alzheimer’s Disease Therapy
Authors: Silva, Ana Paula; Perdigão, Margarida; Espírito Santo, Margarida; Advinha, Ana Margarida
Abstract: Pharmacogenomic Biomarkers as a Source of evidence for Effectiveness and Safety in Alzheimer’s Disease Therapy</description>
    <dc:date>2024-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/10174/41160">
    <title>Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024</title>
    <link>http://hdl.handle.net/10174/41160</link>
    <description>Title: Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024
Authors: Costa, Paula; Advinha, Ana Margarida; Oliveira-Martins, Sofia
Abstract: Managed Entry Agreements (MEAs) are tools designed to reduce clinical uncertainty and mitigate budget impact of often high-cost, innovative medicines. While finance-based MEAs have been widely used, the increasing complexity of therapies has driven the adoption of more sophisticated and tailored agreements, including risk-sharing models. This study aims to characterize the MEAs established to support public coverage decisions for innovative medicines—defined as those containing new active substances—that received marketing authorization between 2014 and 2024 and obtained positive reimbursement decisions in Portugal.</description>
    <dc:date>2025-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/10174/41158">
    <title>Portuguese Global Medicines Access Index 2022: Intercalary Study</title>
    <link>http://hdl.handle.net/10174/41158</link>
    <description>Title: Portuguese Global Medicines Access Index 2022: Intercalary Study
Authors: Oliveira-Martins, Sofia; Advinha, Ana Margarida
Abstract: Portuguese Global Medicines Access Index 2022: Intercalary Study</description>
    <dc:date>2024-01-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

